---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Pharmacokinetics"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Pharmacokinetics. Topics: Time to maximum concentration and half-life in the phase 1 dose escalation, Company-reported half-life of about eight days, Dose proportionality and target-mediated drug disposition, Immunogenicity, and 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Time to maximum concentration and half-life in the phase 1 dose escalation

> “Maximal concentrations (Cmax) were generally reached between 2 and 5 hours after the start of infusion on cycle 1 day 1. Thereafter, the concentration–time profiles declined in a biexponential manner at higher doses, with geometric mean half-life ranging from 14 hours for lower doses associated with target-mediated drug disposition to 84 hours for higher doses.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-2.1.2.6.3-2"></a>

### Company-reported half-life of about eight days

> “The purpose of this expansion cohort was to further support the pharmacokinetic and pharmacodynamic profile of ficerafusp alfa, particularly its eight-day half-life, and the development of a less frequent dose regimen.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

> “Ficerafusp alfa’s half-life of ~ 8 days supports the rationale to explore less frequent dosing schedules”

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="topic-2.1.2.6.3-3"></a>

### Dose proportionality and target-mediated drug disposition

> “Cmax and area under the plasma concentration versus time curve from 0 to 168 hours (AUC0–168h) increased in a slightly more than dose-proportional manner between 64 and 500 mg. However, a nearly dose-proportional increase in Cmax and AUC0–168h was observed between 500 and 1,500 mg. These data suggest that nonlinear clearance is negligible and linear clearance dominates at doses above 500 mg as EGFR is likely fully saturated.”
> “Of note, ficerafusp alfa showed a nonlinear PK profile consistent with target-mediated drug disposition at doses <500 mg. Specifically, nonoverlapping exposures were achieved at 750 and 1,500 mg once weekly dosages.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

> “PK analysis (data not shown) indicated that exposure increased in an approximately dose-proportional manner and all three dosing regimens maintained target therapeutic levels throughout treatment”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-2.1.2.6.3-4"></a>

### Immunogenicity

> “Antidrug antibody incidence (as defined by Shankar and colleagues; ref. 26) ranged between 18% and 27% across all ficerafusp alfa doses in monotherapy and in combination with pembrolizumab.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-2.1.2.6.3-5"></a>

### Nonclinical pharmacokinetics in cynomolgus monkeys

> “Following a single intravenous infusion of BCA101 to cynomolgus monkeys, serum mean maximum concentrations and mean exposures of the molecule increased dose proportionally (Supplementary Fig. S17), with no saturation of the routes of elimination. The observed volumes of distribution (33–74 mL/kg) suggest that BCA101 is well distributed to the tissues. Half-life of BCA101 ranged from 12.9 to 84.5 hours for the doses tested.”

Source: [Boreddy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10236157/)

<a id="topic-2.1.2.6.3-6"></a>

### Dose-selection rationale for 1500 mg weekly

> “As a result, ficerafusp alfa 1,500 mg once weekly was selected as the recommended dosage based on the PK, pharmacodynamic, and preliminary antitumor activity observed at this dosage level and will continue to be assessed for safety and efficacy during dose expansion.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

> “The purpose of these two expansion cohorts was to inform dose selection for our pivotal study, consistent with the objectives of the FDA’s Project Optimus.”
> “The totality of the data suggests that a higher dose of ficerafusp alfa with greater TGF-β inhibition and immune activation drives deeper tumor responses that translate to more durable outcomes for patients. These data supported the selection of 1500mg QW of ficerafusp alfa as the optimal dose to advance into the Phase 3 portion of our FORTIFI-HN01 pivotal trial.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

> “The phase 2 objective was to determine the optimal biological dose (OBD) of ficerafusp alfa through an integrated analysis of safety, tolerability, PK, PD, and efficacy. Following OBD determination (1500 mg QW), the trial transitioned seamlessly into the phase 3 portion with 2:1 randomization (ficerafusp alfa:control).”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

<a id="topic-2.1.2.6.3-7"></a>

### Pharmacokinetic basis for less frequent dosing regimens

> “Based on available PK results from 1,500 to 1,750-mg every-2-week cohorts, the every-2-week dosing regimen is expected to reach non–clinically derived target concentrations (Supplementary Fig. S2A and S2B).”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

> “The growing body of pharmacokinetic, translational and clinical data and exposure-response modeling supports development of a less frequent dose regimen that is designed to optimize efficacy, safety and convenience without compromising the depth nor durability of response that are characteristic of ficerafusp alfa’s differentiated clinical profile.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.1.2.6.3-8"></a>

### Pembrolizumab half-life and steady state

> “Steady-state concentrations of pembrolizumab were reached by 16 weeks of repeated dosing with an every 3-week regimen and the systemic accumulation was 2.1-fold.”
> “The terminal half-life (t1/2) is 22 days (32%).”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
